Cargando…

The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records

AIMS: To investigate whether smokers prescribed varenicline had lower risks of serious ill‐health during the 4 years following treatment compared with those prescribed nicotine replacement therapy (NRT). DESIGN: Observational cohort study of electronic medical records. SETTING: A total of 370 UK gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Neil M., Taylor, Gemma M. J., Taylor, Amy E., Jones, Timothy, Martin, Richard M., Munafò, Marcus R., Windmeijer, Frank, Thomas, Kyla H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969097/
https://www.ncbi.nlm.nih.gov/pubmed/29460494
http://dx.doi.org/10.1111/add.14146
_version_ 1783325905667489792
author Davies, Neil M.
Taylor, Gemma M. J.
Taylor, Amy E.
Jones, Timothy
Martin, Richard M.
Munafò, Marcus R.
Windmeijer, Frank
Thomas, Kyla H.
author_facet Davies, Neil M.
Taylor, Gemma M. J.
Taylor, Amy E.
Jones, Timothy
Martin, Richard M.
Munafò, Marcus R.
Windmeijer, Frank
Thomas, Kyla H.
author_sort Davies, Neil M.
collection PubMed
description AIMS: To investigate whether smokers prescribed varenicline had lower risks of serious ill‐health during the 4 years following treatment compared with those prescribed nicotine replacement therapy (NRT). DESIGN: Observational cohort study of electronic medical records. SETTING: A total of 370 UK general practices sampled from the Clinical Practice Research Datalink. PARTICIPANTS: A total of 126 718 patients aged 18 and over who were issued smoking cessation prescriptions between 1 September 2006 and 31 March 2014. MEASUREMENTS: Our primary outcome was all‐cause mortality within 2 years of first prescription as indicated by linked Office of National Statistics data. Our secondary outcomes were cause‐specific mortality, all‐cause, cause‐specific hospitalization, primary care diagnosis of myocardial infarction or chronic obstructive pulmonary disease (COPD), body mass index and attendance rate to primary care within 2 years of first prescription. Risk differences and 95% confidence intervals were estimated by multivariable adjusted regression and propensity score matched regression. We used instrumental variable analysis to overcome residual confounding. FINDINGS: People prescribed varenicline were healthier at baseline than those prescribed NRT in almost all characteristics, highlighting the potential for residual confounding. Our instrumental variable analysis results found that people prescribed varenicline had a similar risk of mortality at 2 years [risk difference per 100 patients treated = 0.67, 95% confidence interval (CI) = ‐0.11 to 1.46)] to those prescribed NRT, and there were similar rates of all‐cause hospitalization, incident primary‐care diagnoses of myocardial infarction and COPD. People prescribed varenicline subsequently attended primary care less frequently. CONCLUSIONS: Smokers prescribed varenicline in primary care in the United Kingdom do not appear to be less likely to die, be hospitalized or experience a myocardial infarction or chronic obstructive pulmonary disease during the following 2 years compared with smokers prescribed nicotine replacement therapy, but they gain more weight and attend primary care less frequently.
format Online
Article
Text
id pubmed-5969097
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59690972018-05-30 The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records Davies, Neil M. Taylor, Gemma M. J. Taylor, Amy E. Jones, Timothy Martin, Richard M. Munafò, Marcus R. Windmeijer, Frank Thomas, Kyla H. Addiction Research Reports AIMS: To investigate whether smokers prescribed varenicline had lower risks of serious ill‐health during the 4 years following treatment compared with those prescribed nicotine replacement therapy (NRT). DESIGN: Observational cohort study of electronic medical records. SETTING: A total of 370 UK general practices sampled from the Clinical Practice Research Datalink. PARTICIPANTS: A total of 126 718 patients aged 18 and over who were issued smoking cessation prescriptions between 1 September 2006 and 31 March 2014. MEASUREMENTS: Our primary outcome was all‐cause mortality within 2 years of first prescription as indicated by linked Office of National Statistics data. Our secondary outcomes were cause‐specific mortality, all‐cause, cause‐specific hospitalization, primary care diagnosis of myocardial infarction or chronic obstructive pulmonary disease (COPD), body mass index and attendance rate to primary care within 2 years of first prescription. Risk differences and 95% confidence intervals were estimated by multivariable adjusted regression and propensity score matched regression. We used instrumental variable analysis to overcome residual confounding. FINDINGS: People prescribed varenicline were healthier at baseline than those prescribed NRT in almost all characteristics, highlighting the potential for residual confounding. Our instrumental variable analysis results found that people prescribed varenicline had a similar risk of mortality at 2 years [risk difference per 100 patients treated = 0.67, 95% confidence interval (CI) = ‐0.11 to 1.46)] to those prescribed NRT, and there were similar rates of all‐cause hospitalization, incident primary‐care diagnoses of myocardial infarction and COPD. People prescribed varenicline subsequently attended primary care less frequently. CONCLUSIONS: Smokers prescribed varenicline in primary care in the United Kingdom do not appear to be less likely to die, be hospitalized or experience a myocardial infarction or chronic obstructive pulmonary disease during the following 2 years compared with smokers prescribed nicotine replacement therapy, but they gain more weight and attend primary care less frequently. John Wiley and Sons Inc. 2018-02-20 2018-06 /pmc/articles/PMC5969097/ /pubmed/29460494 http://dx.doi.org/10.1111/add.14146 Text en © 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Reports
Davies, Neil M.
Taylor, Gemma M. J.
Taylor, Amy E.
Jones, Timothy
Martin, Richard M.
Munafò, Marcus R.
Windmeijer, Frank
Thomas, Kyla H.
The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records
title The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records
title_full The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records
title_fullStr The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records
title_full_unstemmed The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records
title_short The effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records
title_sort effects of prescribing varenicline on two‐year health outcomes: an observational cohort study using electronic medical records
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969097/
https://www.ncbi.nlm.nih.gov/pubmed/29460494
http://dx.doi.org/10.1111/add.14146
work_keys_str_mv AT daviesneilm theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT taylorgemmamj theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT tayloramye theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT jonestimothy theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT martinrichardm theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT munafomarcusr theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT windmeijerfrank theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT thomaskylah theeffectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT daviesneilm effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT taylorgemmamj effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT tayloramye effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT jonestimothy effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT martinrichardm effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT munafomarcusr effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT windmeijerfrank effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords
AT thomaskylah effectsofprescribingvareniclineontwoyearhealthoutcomesanobservationalcohortstudyusingelectronicmedicalrecords